Active, not recruitingPhase 2NCT05716087
A Study of Rocbrutinib in Participants With Relapse or Refractory Mantle Cell Lymphoma
Studying Mantle cell lymphoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Guangzhou Lupeng Pharmaceutical Company LTD.
- Principal Investigator
- Jun Zhu, MD, PhD, M.D., PhDPeking University Cancer Hospital & Institute
- Intervention
- Rocbrutinib(drug)
- Enrollment
- 62 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2023 – 2026
Study locations (30)
- Anhui provincial cancer hospital, Hefei, Anhui, China
- The first affiliated hospital of Anhui medical university, Hefei, Anhui, China
- Peking University Third Hospital, Beijing, Beijing Municipality, China
- Beijing Cancer Hospital, Beijing, Beijing Municipality, China
- The first affiliated hospital of Chongqing mediacal university, Chongqing, Chongqing Municipality, China
- Fujian Cancer Hospital, Fuzhou, Fujian, China
- Fujian Medical university union hospital, Fuzhou, Fujian, China
- The first affiliated hospital of Xiamen university, Xiamen, Fujian, China
- Gansu provincial cancer hospital, Lanzhou, Gansu, China
- Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
- Meizhou people'shospital, Meizhou, Guangdong, China
- The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China
- The fourth hospital of Hebei medical university, Shijiazhuang, Hebei, China
- Harbin First Hospital, Harbin, Heilongjiang, China
- The First Affiliated Hospital of Henan University of Science & Technology, Luoyang, Henan, China
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05716087 on ClinicalTrials.govOther trials for Mantle cell lymphoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT06675123Pacritinib in Combination With a BTK Inhibitor for the Treatment of Patients With Relapsed or Refractory Mantle Cell LymphomaCity of Hope Medical Center
- RECRUITINGPHASE3NCT07377578A Study of Rocbrutinib Versus Investigator's Choice of BTK Inhibitors in Patients With Relapsed or Refractory Mantle Cell LymphomaGuangzhou Lupeng Pharmaceutical Company LTD.
- RECRUITINGPHASE2NCT07272499Orelabrutinib Plus Lisaftoclax and Rituximab in Untreated Mantle Cell Lymphoma With High-Risk DiseaseRuijin Hospital
- RECRUITINGPHASE2NCT07029737A Study to Evaluate Acalabrutinib, in Combination With the R-CHOP Standard of Care, for Previously Untreated Mantle Cell Lymphoma in SpainAstraZeneca
- RECRUITINGPHASE2NCT07082686A Study to Evaluate the Efficacy and Safety of ICP-248 in Subjects With Relapsed or Refractory Mantle Cell Lymphoma (APEX-06)Beijing InnoCare Pharma Tech Co., Ltd.
- RECRUITINGNANCT07257510Pomalidomide Plus Orelabrutinib and Zuberitamab in Untreated Mantle Cell LymphomaPeking University Third Hospital
- RECRUITINGPHASE2NCT07199296Orelabrutinib and Rituximab With Optional Autologous Hematopoietic Stem Cell Transplantation in MCL TreatmentRuijin Hospital
- RECRUITINGPHASE2NCT06846489Acalabrutinib Plus Rituximab for the Treatment of Elderly or Low- to Intermediate-Risk Younger Untreated Mantle Cell LymphomaSun Yat-sen University